US 12,018,043 B2
CD73 inhibitors
Xiaohui Du, Belmont, CA (US); John Eksterowicz, Burlingame, CA (US); Valeria R. Fantin, Burlingame, CA (US); Daqing Sun, Foster City, CA (US); Qiuping Ye, Foster City, CA (US); Jared Moore, San Rafael, CA (US); Tatiana Zavorotinskaya, Moraga, CA (US); Brian R. Blank, Daly City, CA (US); Yosup Rew, Foster City, CA (US); Kejia Wu, South San Francisco, CA (US); Liusheng Zhu, Foster City, CA (US); Johnny Pham, San Bruno, CA (US); Hiroyuki Kawai, Pacifica, CA (US); and Chien-Hung Yeh, San Bruno, CA (US)
Assigned to ORIC PHARMACEUTICALS, INC., South San Francisco, CA (US)
Filed by ORIC Pharmaceuticals, Inc., South San Francisco, CA (US)
Filed on Oct. 31, 2022, as Appl. No. 18/051,125.
Application 18/051,125 is a division of application No. 17/083,871, filed on Oct. 29, 2020, granted, now 11,530,236.
Claims priority of provisional application 63/088,646, filed on Oct. 7, 2020.
Claims priority of provisional application 62/987,806, filed on Mar. 10, 2020.
Claims priority of provisional application 62/928,138, filed on Oct. 30, 2019.
Prior Publication US 2023/0131747 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 19/23 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC C07H 19/23 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 33 Claims
 
1. A method of treating cancer in a subject, wherein the cancer is selected from lung cancer, melanoma, breast cancer, ovarian cancer, colorectal cancer, gastric cancer, gallbladder cancer, prostate cancer, renal cancer, lymphoma, leukemia, and multiple myeloma, the method comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
Q1 is CW;
Q2 is N and Q3 is N;
W is hydrogen;
R1 and R2 are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R1a;
each R1a is independently halogen, —CN, C1-C6 alkyl, C1-C6 fluoroalkyl, or C1-C6 hydroxyalkyl;
R3 is hydrogen, halogen, —CN, ORb, SRb, C1-C6 alkyl, C2-C6 alkynyl, or C1-C6 hydroxyalkyl; wherein the alkyl and alkynyl is independently optionally substituted with one, two, or three R3a;
each R3a is halogen, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 hydroxyalkyl, or cycloalkyl;
R4 and R5 are —ORb;
R6 is hydrogen, deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 heteroalkyl, or heterocycloalkyl; wherein the alkyl is independently optionally substituted with one, two, or three R6a;
each R6a is —OR13, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 heteroalkyl, cycloalkyl, or heteroaryl;
R7, R8, R9, and R10 are independently hydrogen, deuterium, or C1-C6 alkyl;
X is —O—;
Ring A is heterocycloalkyl or heteroaryl;
each RA is independently halogen, —CN, —ORb, —SRb, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 hydroxyalkyl;
n is 0, 1, 2, 3, or 4;
each R13 is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl;
R21 and R22 are independently hydrogen or C1-C20 alkyl; and
each Rb is independently hydrogen or C1-C6 alkyl.